Roberto Caporali to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Roberto Caporali has written about Tumor Necrosis Factor-alpha.
Connection Strength
2.067
-
20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii5-vii10.
Score: 0.354
-
Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand? Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii1-vii4.
Score: 0.354
-
Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii42-vii53.
Score: 0.354
-
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis. 2018 Feb; 21(2):422-430.
Score: 0.333
-
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol. 2018 May; 28(3):542-549.
Score: 0.329
-
COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020 08; 16(8):465-470.
Score: 0.100
-
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? Autoimmun Rev. 2018 Jan; 17(1):24-28.
Score: 0.083
-
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):919-928.
Score: 0.080
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.079